Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that it has entered into a
multi-million dollar contract with Shire US Manufacturing Inc., a subsidiary
of Shire plc., for the manufacture and supply of specialty pharmaceutical
products to Shire.
Over the course of a three year period commencing on 1 April 2009 Shire plans
to transition several products, including Carbatrol® (carbamezepine), Intuniv™
(guanfacine extended release), Lialda® (mesalamine), Pentasa® (mesalamine) and
Vyvanse™ (lisdexamfetamine dimesylate) from its Owings Mills, Maryland (United
States) facility to DSM Pharmaceutical Product’s facility in Greenville, North
Carolina (United States). There is an initial term of five years for
commercial manufacturing of most products upon completion of a successful
transition.
Jan Zuidam,
Deputy Chairman of the DSM Managing Board said: "This is the level of
partnership that DSM is committed to and represents the strength of our well
established, long term customer relationship with Shire. We believe this deal
represents an endorsement of our competitive cost structure and continuing
commitment to excellence in providing the pharma industry with confidence in
the quality and security of supply that DSM can provide."
Bob Hartmayer, President and CEO of DSM Pharmaceutical Products added: "
The breadth of our capabilities and regulatory excellence allow us to ensure
delivery for our customers drawing on DSM’s expertise, competence and
financial strength. We are thrilled to expand our commercial relationship with
Shire, and look forward to the prospect of future growth at our Greenville
facility.”
DSM will also continue to manufacture Adderall XR® (mixed salts of a
single-entity amphetamine product) and Fosrenol® (lanthanum carbonate) for
Shire and will provide Shire with technical services.
About DSM Pharmaceutical Products
DSM Pharmaceutical Products
is a global provider of high quality custom contract manufacturing and
development services to the pharmaceutical and biopharmaceutical industries.
DSM contract manufacturing services include: chemical development, registered
intermediates, registered starting materials, active pharmaceutical
ingredients (API's), fermentation, mammalian cell production of monoclonal
antibodies and proteins, formulation development, clinical trial manufacturing
and finished dose form manufacturing of solids, semi-solids, and scheduled
drugs, aseptic liquid and lyophilized products. More information:
www.dsmpharmaceuticals.com.